# Yun Ho Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yun-ho-bio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Latest round: Series A (Aug 6, 2025)
- Investors on record: 1

## About

Based in Suzhou, China and founded in 2022, Yunhe Intelligent Medicine (Suzhou) Biotechnology Co., Ltd., dba Yun Ho Bio, is a biopharmaceutical company primarily engaged in the research and development of small nucleic acid drugs with a focus on AI (Artificial Intelligence)-driven RNAi innovative therapy development.

In March 2026, Yun Ho Bio closed a round of strategic investment from Oriza Holdings.

Yun Ho Bio mainly engages in AI-assisted extrahepatic siRNA drug development, medical research and experimental development, and biopharmaceutical R&D. The company has established an AI-assisted end-to-end small nucleic acid drug development platform, a multi-organ targeted delivery system, and a chemical modification platform, enabling cost reduction and efficiency improvement in drug development.

Yun Ho Bio primarily generates revenue through biopharmaceutical R&D combined with comprehensive technical services related to medical technology.

## Funding rounds

- Series A, Aug 6, 2025 — Ennovation Ventures

## Investors

- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A